Zealand Pharma A/S
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZLDPF research report →
Companywww.zealandpharma.com
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management.
- CEO
- Adam Sinding Steensberg
- IPO
- 2013
- Employees
- 385
- HQ
- Copenhagen, DK
Price Chart
Valuation
- Market Cap
- $3.45B
- P/E
- 3.49
- P/S
- 2.41
- P/B
- 1.54
- EV/EBITDA
- 2.80
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.72%
- Op Margin
- 73.88%
- Net Margin
- 69.22%
- ROE
- 42.59%
- ROIC
- 42.14%
Growth & Income
- Revenue
- $9.19B · 14565.56%
- Net Income
- $6.44B · 696.98%
- EPS
- $91.38 · 662.68%
- Op Income
- $7.14B
- FCF YoY
- 786.87%
Performance & Tape
- 52W High
- $83.12
- 52W Low
- $35.93
- 50D MA
- $46.34
- 200D MA
- $63.89
- Beta
- 0.56
- Avg Volume
- 2.15K
Get TickerSpark's AI analysis on ZLDPF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ZLDPF Coverage
We haven't published any research on ZLDPF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ZLDPF Report →